Last reviewed · How we verify
OSELTAMIVIR
Oseltamivir is an antiviral drug that acts against influenza virus.
At a glance
| Generic name | OSELTAMIVIR |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1999 |
Mechanism of action
Oseltamivir is designed to combat influenza viruses. It works by inhibiting the virus's ability to replicate and spread within the body.
Approved indications
Common side effects
- Nausea
- Vomiting
- Headache
- Nausea
- Vomiting
- Headache
- Pain
Key clinical trials
- Post-exposure Influenza Prophylaxis (PHASE3)
- Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting (PHASE3)
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- A/Texas Flu Challenge (PHASE1)
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza (PHASE2)
- Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients (PHASE2)
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)
- Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OSELTAMIVIR CI brief — competitive landscape report
- OSELTAMIVIR updates RSS · CI watch RSS